【2024 ESMO BC】张剑教授解读TNBC:一种方案能否适用于所有患者? 2024年欧洲肿瘤内科学会乳腺癌年会(2024 ESMO BREAST CANCER Annual Congress)已于德国柏林圆满落幕。在这次盛会的教育专场中,来自剑桥大学肿瘤学系的Helena Earl教授就“TNBC...
[8] Shanu Modi, et al. Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician’s Choice (TPC) in Patients With HER2-Low Unresectable and/or Metastatic Breast Cancer: Updated Survival Results of the Randomized, Phase 3 DESTINY-Breast04 Study. 2023 ESMO, abstract 376O. [9] Modi S,...
Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. PMID: 32517735; PMCID: PMC7285581. [2]Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol. 2022 Jan ...
[2]Bardia A, et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.2022 ASCO.Abatract 1071 [3]Modi S, Jacot W, Yamashita T...
参考文献 1.Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. 2.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. 3.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. ...
②So, Jae Young et al. “Triple negative breast cancer （TNBC）: Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.” Pharmacology & therapeutics vol. 237（2022）: 108253. doi:10.1016/j.pharmthera.2022.108253 ③拓益速递 | 君实生物特瑞普利单抗用于治疗晚期三...
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC) 依沃西单抗联合化疗作为TNBC一线治疗的安全性和有效性 报告人:王晓稼教授 浙江省肿瘤医...
[2]Jiang YZ, Ma D, Suo C, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428-440.e5. doi:10.1016/j.ccell.2019.02.001 [3]Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-neg...
The overall management of breast cancer will increasingly require an understanding of breast cancer heterogeneity, the biological nature of any given tumor as well the existence of increased personalized treatment options. In the current review, focus is directed towards novel targeted strategies for ...
原文出处:FDA Approves KEYTRUDA? (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery...